| Literature DB >> 28963103 |
T Cheng1, X-L Zhang2, J-J Hu3, B Li4, Q Wang2.
Abstract
OBJECTIVES: Surgeons face a substantial risk of infection because of the occupational exposure to blood-borne pathogens (BBPs) from patients undergoing high-risk orthopaedic procedures. This study aimed to determine the seroprevalence of four BBPs among patients undergoing joint arthroplasty in Shanghai, China. In addition, we evaluated the significance of pre-operative screening by calculating a cost-to-benefit ratio.Entities:
Keywords: Blood-borne pathogens; Joint arthroplasty; Pre-operative screening
Year: 2017 PMID: 28963103 PMCID: PMC5630999 DOI: 10.1302/2046-3758.69.BJR-2017-0066.R2
Source DB: PubMed Journal: Bone Joint Res ISSN: 2046-3758 Impact factor: 5.853
The socio-demographic characteristics of patients.
| Characteristics | HBV positive (%) | HCV positive (%) | HIV positive (%) | TP positive (%) |
|---|---|---|---|---|
| Age group (yrs) | ||||
| 18 to 34 | 24/521 ( | 2/521 ( | 3/521 ( | 13/521 ( |
| 35 to 54 | 97/1497 ( | 6/1497 ( | 5/1497 ( | 46/1497 ( |
| 55 to 74 | 401/7329 ( | 32/7329 ( | 1/7329 ( | 256/7329 ( |
| > 74 | 113/2262 ( | 12/2262 ( | 0/2262 ( | 102/2262( |
| Gender | ||||
| Male | 258/4178 ( | 23/4178 ( | 5/4178 ( | 125/4178 ( |
| Female | 377/7431 ( | 29/7431 ( | 4/7431 ( | 292/7431 ( |
| Procedure | ||||
| Hip | 383/7290 ( | 30/7290 ( | 7/7290 ( | 278/7290 ( |
| Knee | 241/4096 ( | 22/4096 ( | 2/4096 ( | 135/4096 ( |
| Shoulder | 9/191 ( | 0/191 ( | 0/191 ( | 3/191 ( |
| Elbow | 2/32 ( | 0/32 ( | 0/32 ( | 1/32 ( |
| Local origin | ||||
| Urban | 361/6971 ( | 27/6971 ( | 4/6971 ( | 275/6971 ( |
| Rural | 274/4638 ( | 25/4638 ( | 5/4638 ( | 142/4638 ( |
| Blood/blood product transfusion | ||||
| History | 136/2176 ( | 35/2176 ( | 4/2176 ( | 81/2176 ( |
| No history | 493/9433 ( | 17/9433 ( | 5/9433 ( | 336/9433 ( |
| Marital status | ||||
| Unmarried (never married, divorced, widowed) | 73/1491 ( | 7/1491 ( | 1/1491 ( | 63/1491 ( |
| Married | 562/10118 ( | 45/10118 ( | 8/10118 ( | 354/10118 ( |
| Totals | 635/11609 ( | 52/11609 ( | 9/11609 ( | 417/11609 ( |
HBV, Hepititis B virus; HCV, Hepititis C virus; HIV, Human immunodeficiency virus; TP, Treponema pallidum
Fig. 1Graph showing the distribution of Hepatitis B virus seroprevalence among patients by age (years) and gender.
Theoretical calculation of transmission risk and the cost-to-benefit ratio of pre-operative screening.
| Virus | Seroconversion rate (%) (S) | Seroprevalence (%) (P) | Risk of accidental transmission (%) (S×P) | Cumulative risk[ | Patients screened (n) | Screening costs (Chinese Yuan Renminbi) |
|---|---|---|---|---|---|---|
| HBV | 406 to 6094 | 10 556 to 158 444 | ||||
| HCV | 14 815 to 222 222 | 1 481 500 to 22 222 200 | ||||
| HIV | 2 777 778 to 41 666 667 | 166 666 680 to 2 500 000 020 |
for a surgeon operating over a period of 40 years on patients and having a mean of ten percutaneous blood contacts per year
HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; S, Seroconversion of single occupational exposure; P, Seroprevalence of blood-borne virus infection in patients
Seroprevalence of blood-borne viruses in patients undergoing orthopaedic surgery.
| Author | Country | Publication year | Patients (n) | HBV (%) | HCV (%) | HIV (%) |
|---|---|---|---|---|---|---|
| Calore et al[ | USA | 2012 | 381 | NA | NA | |
| DelSole et al[ | USA | 2014 | 14772 | NA | NA | |
| Issa et al[ | USA | 2015 | 1 700 400 | NA | NA | |
| Khan et al[ | Pakistan | 2007 | 1630 | NA | ||
| Lin et al[ | USA | 2013 | 5 681 024 | NA | NA | |
| Mineiro et al[ | Portugal | 1997 | 288 | |||
| Simonian et al[ | USA | 1995 | 425 | NA | NA | |
| Thorburn et al[ | UK | 2003 | 967 | NA | NA | |
| Utkan et al[ | Greece | 2006 | 1040 | NA | ||
| Villani et al[ | Italy | 2001 | 911 | NA | ||
| Weber et al[ | Germany | 2013 | 10 011 | |||
| Wiegand et al[ | Germany | 2006 | 2026 | NA | NA | |
| Winkelmann et al[ | Germany | 2016 | 1534 | |||
| Yeganeh et al[ | Iran | 2015 | 320 | |||
| Our study | China | 2017 | 11 609 |
newly recognised infections
HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; NA, not available